High-Potency APIs: Containment and Handling Issues - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

High-Potency APIs: Containment and Handling Issues
The author explains the planning, equipment, and facility design requried for manufacturing HPAPIs and specialized requirements for handling these compounds.

Pharmaceutical Technology

Third-party certification. Companies handling HPAPIs should also consider being certified by a third-party organization such as SafeBridge. This certification process allows for all aspects of the potent compound-handling program to be evaluated against current industry expectations by independent experts. As an added benefit, certification can also lead to continuous improvement and evaluation programs designed to ensure advancement of the HPAPI-handling systems. Even if the company chooses not to go through the certification process, they still may choose to have an evaluation by third-party experts as an effective means of identifying gaps or opportunities for improvement in the HPAPI program.


The development and manufacture of high-potency active pharmaceutical ingredients (HPAPIs) requires significant planning, extensive employee training, proper equipment, and facility design as well as implementation of the necessary procedures to safely handle the compounds. The capital investments are significant, and the knowledge gained through experience is invaluable. Robust systems must be employed in all aspects of the HPAPI-handling program, from initial project evaluation through equipment cleaning, to disposal of process wastes. As the number of potent compounds in pharmaceutical development continues to increase, so will the opportunities for HPAPI manufacturers, especially for companies with capabilities in growing niche areas such as HPAPI–antibody conjugation.

David Bormett is director of regulatory affairs at SAFC Pharma, 645 Science Drive, Madison, WI 53711, tel. 608.233.3115, fax 608.233.6873,


1. P. Van Arnun, "Charting API Market Growth and Opportunity," Pharm. Technol. 32 (7), 58–61 (2008)

2. A. Thayer, "Contained Chemistry," C&EN, 86 (24), 17–27 (2008).

3. P. Van Arnun, "Investing in High-Potency Manufacturing," Pharm. Technol. 31 (11), 54–58 (2008)

4. A.W. Ader, J.J. Mason, and J.P. Farris, "Important Elements in Evaluating Contract Manufacturing Organizations," Chem. Today 25 (2), 56–60 (2007).

5. B.D. Naumannet et al., "Performance-Based Exposure Control Limits for Pharmaceutical Active Ingredients," Amer. Indust. Hyg. Jour. 57 (1) 33–42 (1996).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here